|
Search for our Investigators on Pub
Med
|
DAVID REISMAN, Ph.D. Lab
LAB PERSONNEL
David Reisman, Ph.D. - Associate Professor, USC
PUBLICATIONS
Boggs K, Reisman D. Increased p53 transcription prior to DNA
synthesis is regulated through a novel regulatory element
within the p53 promoter. Oncogene. 2005 Sep 12.
Reisman D, McFadden JW, Lu G. Loss of heterozygosity and p53
expression in Pterygium. Cancer Lett. 2004 Mar
31;206(1):77-83.
Edwards J, Lorenz KT, Remington BA, Pollaine S, Colvin J,
Braun D, Lasinski BF, Reisman D, McNaney JM, Greenough JA,
Wallace R, Louis H, Kalantar D. Laser-driven plasma loader
for shockless compression and acceleration of samples in the
solid state. Phys Rev Lett. 2004 Feb 20;92(7):075002.
Durland-Busbice S, Reisman D. Lack of p53 expression in
human myeloid leukemias is not due to mutations in
transcriptional regulatory regions of the gene. Leukemia.
2002 Oct;16(10):2165-7.
Reisman D, Eaton E, McMillin D, Doudican NA, Boggs K.
Cloning and characterization of murine p53 upstream
sequences reveals additional positive transcriptional
regulatory elements. Gene. 2001 Aug 22;274(1-2):129-37.
Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF,
Jaffee E, Marks J, Sukumar S. Compromised HOXA5 function can
limit p53 expression in human breast tumours. Nature. 2000
Jun 22;405(6789):974-8.
Loging WT, Reisman D. Inhibition of the putative tumor
suppressor gene TIMP-3 by tumor-derived p53 mutants and wild
type p53. Oncogene. 1999 Dec 9;18(52):7608-15.
Loging WT, Reisman D. Elevated expression of ribosomal
protein genes L37, RPP-1, and S2 in the presence of mutant
p53. Cancer Epidemiol Biomarkers Prev. 1999
Nov;8(11):1011-6.
Reisman D, Loging WT. Transcriptional regulation of the p53
tumor suppressor gene. Semin Cancer Biol. 1998;8(5):317-24.
Reisman D, Balint e, Loging WT, Rotter V, Almon E. A novel
transcript encoded within the 10-kb first intron of the
human p53 tumor suppressor gene (D17S2179E) is induced
during differentiation of myeloid leukemia cells. Genomics.
1996 Dec 15;38(3):364-70.
Roy B, Reisman D. Positive and negative regulatory elements
in the murine p53 promoter. Oncogene. 1996 Dec
5;13(11):2359-66.
Ying Z, Reisman D, Buggy J. AP-1 DNA binding activity
induced by hyperosmolality in the rat hypothalamic
supraoptic and paraventricular nuclei. Brain Res Mol Brain
Res. 1996 Jul;39(1-2):109-16.
Balint E, Reisman D. Increased rate of transcription
contributes to elevated expression of the mutant p53 gene in
Burkitt's lymphoma cells. Cancer Res. 1996 Apr
1;56(7):1648-53.
Uittenbogaard MN, Giebler HA, Reisman D, Nyborg JK.
Transcriptional repression of p53 by human T-cell leukemia
virus type I Tax protein. J Biol Chem. 1995 Dec
1;270(48):28503-6.
Roy B, Reisman D. Inducible expression of Mad accelerates
growth arrest of serum deprived human glioblastoma cells.
Cell Biol Int. 1995 Apr;19(4):307-13.
Roy B, Beamon J, Balint E, Reisman D. Transactivation of the
human p53 tumor suppressor gene by c-Myc/Max contributes to
elevated mutant p53 expression in some tumors. Mol Cell
Biol. 1994 Dec;14(12):7805-15.
Reisman D, Elkind NB, Roy B, Beamon J, Rotter V. c-Myc
trans-activates the p53 promoter through a required
downstream CACGTG motif. Cell Growth Differ. 1993
Feb;4(2):57-65.
Reisman D, Rotter V. The helix-loop-helix containing
transcription factor USF binds to and transactivates the
promoter of the p53 tumor suppressor gene. Nucleic Acids
Res. 1993 Jan 25;21(2):345-50.
Ronen D, Rotter V, Reisman D. Expression from the murine p53
promoter is mediated by factor binding to a downstream
helix-loop-helix recognition motif. Proc Natl Acad Sci U S
A. 1991 May 15;88(10):4128-32.
Reisman D. Nuclear factor-1 (NF-1) binds to multiple sites
within the transcriptional enhancer of Moloney murine
leukemia virus. FEBS Lett. 1990 Dec 17;277(1-2):209-11.
Reisman D, Rotter V. Two promoters that map to 5'-sequences
of the human p53 gene are differentially regulated during
terminal differentiation of human myeloid leukemic cells.
Oncogene. 1989 Aug;4(8):945-53.
Reisman D, Rotter V. Induced expression from the Moloney
murine leukemia virus long terminal repeat during
differentiation of human myeloid cells is mediated through
its transcriptional enhancer. Mol Cell Biol. 1989
Aug;9(8):3571-5.
Reisman D, Greenberg M, Rotter V. Human p53 oncogene
contains one promoter upstream of exon 1 and a second,
stronger promoter within intron 1. Proc Natl Acad Sci U S A.
1988 Jul;85(14):5146-50.
Shohat O, Greenberg M, Reisman D, Oren M, Rotter V.
Inhibition of cell growth mediated by plasmids encoding p53
anti-sense. Oncogene. 1987;1(3):277-83.
Reisman D, Sugden B. trans activation of an Epstein-Barr
viral transcriptional enhancer by the Epstein-Barr viral
nuclear antigen 1. Mol Cell Biol. 1986 Nov;6(11):3838-46.
Reisman D, Yates J, Sugden B. A putative origin of
replication of plasmids derived from Epstein-Barr virus is
composed of two cis-acting components. Mol Cell Biol. 1985
Aug;5(8):1822-32.
Reisman D, Sugden B. An EBNA-negative, EBV-genome-positive
human lymphoblast cell line in which superinfecting EBV DNA
is not maintained. Virology. 1984 Aug;137(1):113-26.
Yates J, Warren N, Reisman D, Sugden B. A cis-acting element
from the Epstein-Barr viral genome that permits stable
replication of recombinant plasmids in latently infected
cells. Proc Natl Acad Sci U S A. 1984 Jun;81(12):3806-10.
Buell GN, Reisman D, Kintner C, Crouse G, Sugden B. Cloning
overlapping DNA fragments from the B95-8 strain of
Epstein-Barr virus reveals a site of homology to the
internal repetition. J Virol. 1981 Dec;40(3):977-82.
For recent
abstracts, click here
|
